A survey of the diagnosis, management, and patterns of care for brain tumors is particularly pertinent now. The past decade has seen an explosion in diagnostic imaging technology and this has led to greatly increased accuracy of detection and specific care for patients suffering from brain tumors. Other advances in medical technology, including the laboratory diagnosis of neuroendocrine disorders and the development of various types of tumor markers, along with technological advances in surgery, radiation therapy, and chemotherapy have all combined to improve the outlook for patients with tumor involving the central nervous system (CNS).
A study of the Joint Section on Central Nervous System Tumors of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons and the Commission on Cancer of the American College of Surgeons.
In 1977, the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) received the report of a Survey of Intracranial Neoplasms conducted by Westat, Inc? That survey of a representative sample of hospitals in the United States during 1973 and 1974 reported the following important conclusions: 1) there was a national incidence of 35,000 new brain-tumor cases per year, or a rate of 16.7 per 100,000 population; 2) excluding metastatic tumors, pituitary tumors, and histologically unconfirmed lesions, there was an incidence of primary confirmed brain tumors of 15,000 new cases per year, or 7.3 per 100,000 population; 3) there was a national incidence of 62,000 total cases; 4) the male incidence was higher than that in females; 5) the Caucasian incidence was higher than that for blacks, except for benign cases; 6) incidence rates increased with age up to 65 years, except for a peak at the very youngest ages for primary tumors; 7) of the more common histological types of primary tumors, 29% were glioblastoma multiforme (GBM), 18% were meningiomas, 11% were anaplastic astrocytomas (AA), and 9% were astrocytomas; 8) the most frequent primary origins for metastatic tumors were the lung, breast, and genitourinary tract; 9) a 1.8-year mean survival period was noted for all cases: 10) there was an aggregate number of 39 days of hospital care per case, accounting for a total of 1,360,000 days of hospital care per year; 11) an estimated total of 162,000 diagnostic tests were performed on these patients per year; 12) over 16,000 craniotomies were carried out per year on brain-tumor patients; 13) the direct costs for the care of intracranial neoplasms amounted to $185.7 million per year (in 1973 dollars); and 14) the indirect costs of brain tumors (for example, loss of income and loss to the economy) amounted to $138.8 million per year (in 1973 dollars).
Based on the accurate epidemiological studies having been performed and currently underway, the need for additional data to improve diagnosis and therapy becomes evident. The categorization of such data has depended upon various classification efforts which have previously been applied to the problem of brain tumors. The World Health Organization (WHO) has reviewed the pathology of tumors of the CNS and has reached a worldwide consensus with regard to nomenclature and tissue grading. 6 In addition, the American Joint Committee on Cancer (AJCC) in association with the Union lnternationale Contre Cancer has devised a staging and end-results reporting system for CNS tumors which has been generally accepted and is currently being applied in a number of different studies.
The epidemiological and classification efforts both reflect advances that have occurred in brain-tumor diagnosis. With further education of the medical professional community and the patient population in general, clinical acumen has steadily improved and brain tumors that become symptomatic are being diagnosed at earlier and earlier stages. Early diagnosis is, of course, particularly enhanced by the use of imaging techniques such as computerized tomography (CT) and magnetic resonance (MR) imaging. Early diagnosis combined with advances in brain-tumor therapy have led to a better overall outlook for patients. One of the values of a survey such as that conducted by the Commission on Cancer of the American College of Surgeons (ACS) is to test the actual impact of these advances in the care of patients.
Advances in surgical technique have included the use of lasers, intraoperative diagnostic ultrasound, computer-guided stereotaxis, and methods of clinical electrophysiology applied to the monitoring of normal function. Advances in radiation therapy have included the use of radiation sensitizers, techniques of hyperfractionation, stereotactic radiation implants, high linear energy transfer radiotherapy, and external stereotactic radiation therapy using linear accelerators or the "gamma knife." Advances in chemotherapy have included the use of selective infusions, the development of new agents, and the use of regimens that include rescue and protection of the patient from the adverse effects of intensive chemotherapy. Advances in immunotherapy have included the use of sensitized cells and humoral agents, and there have been advances in other modalities that appear promising such as photoradiation and hyperthermia. For the above reasons, survey data are of significant importance in providing baseline information regarding the patterns of care, the patterns of failure, and data which can be the basis of planning new therapy for brain tumors.
In 1985, the Joint Section on Central Nervous System Tumors of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons proposed to the Committee on Patient Care and Research of the Commission of Cancer of the ACS that a modern survey be conducted for the following purposes: 1) to determine the relative frequencies of the various histopathological types; 2) to relate the occurrence of various types of brain tumors to age, sex, race, intracranial location, symptom complex, neurological findings, and family history of neoplasia; 3) to review the current use of neurodiagnostic studies; 4) to survey the various forms of therapy and their impact (as well as other correlations) upon disease progression and periods of survival; 5) to evaluate the use of the staging system of the AJCC; and 6) to relate care of brain-tumor patients to hospital facilities and personnel.
Study Methods
The data examined herein were obtained through an audit and survey program conducted by the Committee on Patient Care and Research of the ACS Commission on Cancer. In each of their annual studies, data on the patient, disease, treatment, and outcome characteristics for a particular cancer are obtained from the large number of hospitals which participate in the Hospital Cancer Program activities of the ACS. The general format of these national surveys has been reported and several previous studies have been published including those concerning cancers of the breast, prostate, endometrium, cervix, testis, colon, and rectum? The present study was conducted in 1986 and focused exclusively on primary brain tumors.
The data were abstracted and reviewed by the registry staff of the cancer programs in the reporting hospitals using a form devised and pretested by the Regional Field Staff of the Commission on Cancer in consultation with the neurosurgeon authors of this paper. The study forms requested data for two distinct periods. In order to assess the most recent patterns of care, reporting hospitals were requested to submit data on all primary brain tumors diagnosed in 1985 and, in order to assess trends across time and patient survival patterns, similar data were requested for all brain-tumor patients initially diagnosed in 1980. The most recent data are hereafter referred to as "the short-term survey," and data on the earlier cases are called "the long-term survey." Overall, 679 different hospitals participated in one or both of these studies. Thirty-three hospitals contributed to the long-term (1980) survey alone, 136 to the shortterm (1985) survey alone, and 510 to both the longand short-term studies. The participating hospitals were broadly distributed with respect to size and type of sponsorship, although there was not necessarily a geographic representation of population distribution. Thirteen percent were classified as governmental, nonfederal institutions; 5.2% were governmental, federal institutions; 79.3% were nongovernmental, not-forprofit institutions; and 2.6% were nongovernmental, for-profit institutions. Thirty-one percent of the hospitals had less than 300 beds, 41.2% had 300 to 499 beds, and 27.3% had 500 or more beds. Of the patients included in the survey, 16.4% were from hospitals with less than 300 beds, 36.0% from 300-to 499-bed hospitals, and 47.6% from hospitals with at least 500 beds. Only histologically confirmed and specified primary brain tumors initially diagnosed at each hospital were accepted for analysis. The long-term study provided information on 4764 such patients and the short-term study included 6421 patients, for a total of 11,185 brain-cancer patients. After being received in the offices of the ACS, the data were transmitted to the Department of Cancer Control and Epidemiology at Roswell Park Memorial Institute for processing and analysis. The patients were classified according to the histopathological type of primary brain tumor following the schema developed by the WHO. In the survival analyses of the long-term study, actuarial survival was computed according to the Kaplan and Meier methodologyfl
Results

Histology, Age, Sex, Race, and Family History
The total number of patients, mean and median ages, and sex incidences for each WHO histopathology classification for combined 1980 and 1985 data are shown in Table 1 . The mean (median) age for the 1980 and 1985 groups was 51.2 (56.0) years and 52.6 (58.0) years, respectively, but Table 1 shows that the classic "childhood" brain tumors (germinomas, pineal tumors, piloid astrocytomas, medulloblastomas, and neuroblastomas) occurred at the youngest ages. Glioblastomas multiforme occurred at the oldest mean (median) age, being 60.2 (62.0) years, and patients with astrocytomas and AA had mean and median ages a decade younger (p < 0.010). Five-year survival rates for patients less than 15 Table 2 for four histological types. For patients with GBM, astrocytoma, or meningioma, 5-year survival rates were best at younger ages, except for the poor survival rates of the small number of children with GBM.
Overall, the male/female sex ratio for all brain tumors was 1:1. Table 1 shows a marked female predominance in cases of meningiomas and neurilemomas, as well as in the relatively small number of neuroepitheliomas and chordomas. Striking male predominance was evident for germinomas, pineoblastomas, malignant choroid plexus papillomas, and neuroblastomas, and a less impressive male predominance was seen for pinealomas, mixed gliomas, ependymomas, oligodendrogliomas, and medulloblastomas.
Currently, 83.2% of the population of the United States is Caucasian and 11.7% is black; the percentage of each of these two races with brain tumors was more heavily weighted toward Caucasians. Of the 3094 patients with GBM, 95.4% were Caucasian, 4.1% black, and 0.5% of other races. Among the 2975 patients with astrocytoma, 86.7% were Caucasian, 4.9% black, and 8.4% of other races. There were 2453 patients with meningioma, of whom 87.3% were Caucasian, 9.5% black, and 3.2% of other races. Of the 248 patients with medulloblastoma, 90.3% were Caucasian, 7.8% black, and 1.9% of other races. The interpretation of these data as regards brain-tumor incidence by race might be influenced by a possible lack of geographic representation of surveyed hospitals as it relates to population and by racial differences in at-risk numbers of age groups where brain tumors have peak incidences.
A family history of cancer was recorded in 16% to 19% of cases, probably quite close to what one would expect for any hospital-based population in the United States, although considerable data were missing (35% of cases). When correlated with histopathological type, a 30% to 33% positive family history of cancer was apparent among patients with GBM, malignant lymphoma, and neuroblastoma. A family history of neurofibromatosis was found in 1.6% of all cases, with a slightly higher percentage (2.0%) for patients with neurilemomas. 
Tumor Location
Primary brain tumors occurred in the midline of the brain in 10% of cases, with the rest being about equally distributed on the fight and left sides. The midline location was noted in more than 50% of germinoma, pinealoma/pineocytoma, pineoblastoma, and medulloblastoma cases. For all supratentorial lobes involved, there was a slight but consistent right-sided predominance, and the higher midline involvement for frontal lobe tumors (p < 0.001) probably reflects the tendency for these tumors to cross from side to side in the corpus callosum (Table 3) . For all tumors, there was a 4.2:1 ratio of supratentorial to infratentorial location. Not surprisingly, the infratentorial location predominated for hemangioblastomas (80%), papillomas (53%), pilocytic astrocytomas (52%), medulloblastomas (82%), and neurilemomas (80%).
Of the primary brain sites of tumor occurrence, the frontal lobe was most common, the temporal and parietal lobes were next in frequency, and the occipital lobe least frequent (p < 0.01) ( Table 4 ). More detailed analysis by histopathological type showed the expected high incidence of hemangioblastomas and medulloblastomas in the cerebellum, the ventricular location for ependymal tumors and papillomas, as well as the tendency for mixed gliomas and oligodendrogliomas to 
originate in the frontal lobes. Table 5 not only shows a better 5-year survival rate for low-grade astrocytomas and meningiomas when compared to AA or GBM, but also demonstrates the high percentage of 5-year survivors for ventricular and cerebellar tumors. For GBM's, an occipital lobe location was associated with the best survival among supratentorial tumors, with parietal lobe location being the worst (p < 0.05).
Symptoms
The most common symptoms in patients with brain tumors are headache (54%), seizures (26%), and/or progressive neurological functional loss (68%), with motor weakness being the most common focal complaint (45 %). Headache was a more frequently reported symptom (75% to 80%) in those tumors likely to produce ventricular obstruction and hydrocephalus (germinomas, hemangioblastomas, ependymomas, and medulloblastomas). Progressive neurological functional loss was most frequent in cases of invasive and destructive GBM (78%), and seizures were most frequent (55%) in cases of mixed glioma, oligodendroglioma, and ganglioglioma. When categorized by tumor location, headache was observed most often in cases of cerebellar tumors (70%), where obstructive hydrocephalus is more likely to occur; progressive functional loss was associated mostly with parietal lobe tumors (75 %), where so many cognitive and performance functions reside; and seizures were most frequently connected with frontal lobe tumors (36%).
Modes of Diagnosis and Staging Procedures
A comparison of neurodiagnostic studies performed in 1980 versus 1985 (Table 6 ) revealed the increasing use of MR imaging and the diminishing use of skull xray studies, electroencephalography, angiography, and isotope brain scans. In 92% of studied patients for each survey year, only one intracranial lesion was detected; when multiple tumors were found, the histopathology was most likely to be lymphoma: 22 (16%) of 135 cases. Extracranial extension of primary brain tumors was rare (3%), occurring most frequently in neuroblastoma ( 17.6 %), primitive polar spongioblastoma ( 1 1.5 %), pinealoma/pineocytoma (11.1%), malignant neurilemoma (11.1%), and ependymoma (7.0%). An attempt was made to ascertain tumor size; however, since most of these data (43%) were obtained from pathology reports rather than neurodiagnostic studies, the sizes reported are probably smaller than actually existed. An attempt was made to determine if AJCC staging had been used in the recording of primary brain tumors. In most (48%) instances staging had not been performed by a physician and, instead, was done by the tumor registrar. Even so, greater than 75% of the cases for 1980 or 1985 were not staged. It was of interest that the anaplastic forms of ependymomas, astrocytomas, and oligodendrogliomas presented at a higher clinical stage than their more benign counterparts. Five-year survival data comparing the admission clinical stage to the histopathology were sparse, but these factors tended to correlate in the case of malignant tumors.
Performance Status
The Karnofsky functional rating for all cases was most commonly 80 to 90, and there tended to be a higher percentage of patients with Karnofsky ratings of 60 or higher in the 1985 than in the 1980 survey (Table  7) . A larger percentage of the patients with malignant tumors tended to have Karnofsky ratings less than 70 (Table 8 ). For the most malignant cases (GBM), patients with tumors in the occipital lobe had significantly higher Karnofsky ratings (p < 0.005) than those with tumors in other lobes. Karnofsky ratings tended to be higher in the 15-to 34-year age range, declining with increasing age and in the childhood age group (< 15 years) ( Table 9) .
Karnofsky functional ratings were analyzed at the start and at the finish of initial primary therapy for each of the tumor types, and the data from three tumor types are shown on Table 10 . The patients with GBM who were most intensively treated (surgery, radiotherapy, and chemotherapy) had the highest initial Karnofsky ratings. It was of interest that Karnofsky ratings were usually lower at the conclusion of therapy compared to the start (p < 0.001). For the large group of patients with GBM, less than 20% had Karnofsky ratings greater than 70 at the time of subsequent progression of disease, regardless of their initial primary therapy. For the major histological types, 5-year survival rates were significantly better (p < 0.001) for patients with initial Karnofsky ratings greater than 70 (Table 1 1 ). Table 7 . t Sample size too small.
Treatment
Of all treatments for all brain-tumor patients, surgery alone was the most frequent (45% of cases) followed by surgery plus radiotherapy (36% of cases); there was no major shift in pattern from 1980 to 1985. In total, 97% of patients underwent surgery eactl year. The most common procedure was subtotal resection. Biopsy only was most common for lymphomas, subtotal resection most common for gliomas, total resection most common for hemangioblastomas and meningiomas, and shunt placement most common for pineal and ventricular tumors. For GBM and astrocytomas, tumors in the temporal lobe were more likely to have been totally resected, and patients with medulloblastomas and meningiomas were most likely to have undergone total resections at the sites where these tumors predominate (that is, the cerebellum and parietal areas, respectively). The extent of resection was age-dependent (more complete resections for younger patients) only for patients with GBM, and higher Kamofsky ratings were associated with a larger percentage of total resections in all major histological types. When 5-year survival rates were analyzed regarding type of surgery for the four major histological types, the longest survival periods followed total resection attempts (Table 12) .
Surgical complications were similar in 1980 and 1985, with an increase in neurological deficit being most frequently seen (Table 13) . Infection rates were less than 2%. Hemorrhage at the operative site was seen with a slightly higher than average frequency in patients with hemangiomas (6.7%), which may correlate with the recently recognized association of meningiomas with plasminogen activator factor and disseminated intravascular coagulopathy. 4 The incidence of reoperation at the time of tumor progression varied considerably by histological type. Ependymomas (44%), oligodendrogliomas (43%), meningiomas (45%), and neurilemomas (75%) were often subjected to reoperation at the time of recurrence, and gliomas of low grade were more often operated on at recurrence than high-grade lesions (33% vs. 14%). In the majority of 3  134  5  astrocytoma  23  218  27  meningioma  63#  11  78  medulloblastoma  50?  2  48?   809  8  230  0  0  638  52  195  35f  17  161  96  696  50#  2  51  77#  22  33t  3   28t  8  0  0  6it  42  93~  17  65t  9  76~  10  88t 18 57# 7 * Values are percentages of the total (No.) in each group. ~ SampIe size too small. Radiotherapy was administered to 48% of all patients with brain tumors for each year surveyed. Between 1980 and 1985, there was a shift toward treatment with linear accelerator and less use of a cobalt source. The use of brachytherapy tripled during that 5-year period from 0.5% to 1.9% of cases. Radiation therapy was most often administered to gliomas, germinomas, and medulloblastomas; only 3% of meningiomas received radiotherapy as part of initial therapy. Radiotherapy treatment schedules varied greatly depending upon the histological type, patient's age, tumor location, and radiotherapist's preference. Most schedules involved either a smaller dose to the whole brain with a boost to the tumor area or the entire dose to the whole brain (non-boosted). The mean total dose to the whole brain was lower (4000 to 4600 rads) in the boosted cases than in the non-boosted cases (5000 to 5500 rads). Cytopenia was the complication most often seen in medulloblastoma cases, undoubtedly secondary to neuraxis radiotherapy with marrow suppression; a higher incidence of treatment for the complication was also necessary in this group (Table 14) . Neurological decline during radiotherapy was most often seen in GBM patients ( 12 %).
Eight hundred patients with GBM or AA received chemotherapy, representing approximately 13.5% of all patients in these two histological types. Of all patients with either anaplastic gliomas or medulloblastomas, 11.9% received chemotherapy. Significant complications following chemotherapy were infrequent (< 2%). The involvement by brain-tumor patients in an investigative clinical protocol was surveyed for 1980 and 1985. There appears to have been no significant increase in such involvement (_ 5%) for all patients between the two years surveyed. Assuming that the majority of patients eligible for investigative protocols during both 1980 and 1985 would have been those with anaplastic glial tumors (3703 cases) and medulloblastomas (248 cases), it seems that approximately 7.6% of the maximum number of eligible patients are being placed in investigative protocols. From the information available, however, it appears that the 111 GBM patients who were involved in investigative protocols had an almost threefold (12%) higher 5-year survival rate compared to the 1070 who were not (4.5%).
Of the 2871 patients known to have died during the two survey years, 8.5% had autopsies performed. The 5-year survival rates of 1980 patients are shown in Table 15 .
Patient Care Facilities
Each patient report was linked to data on the patient care personnel and facilities available where the patient was treated. These data were analyzed with categories of hospital size as measured by the number of medical/ surgical beds. Overall, greater than 95% of patients received care where there were attending neurosurgeons and neurologists (Table 16 ). Except for those hospitals with less than 300 beds, the majority had neuroradiologist attendings. Only in hospitals with at least 500 beds did the majority of patients have available neuro-ophthalmologist, neuroanesthesiologist, or neuropathologist attendings. The occurrence of neurosurgically trained registered nurses on duty on the wards and in the operating rooms increased with hospital size. Regardless of hospital size, the great majority of patients were treated where staff included medical oncologists, radiologists, endocrinologists, and otolaryngologists. Regarding neurosurgical facilities, patients with brain tumors were more likely to be treated in a designated inpatient ward, operating room, and intensive care unit in larger-sized hospitals (Table 17) .
Most patients had access to angiography, CT, electroencephalography, ultrasound, and nuclear medicine scanning but the availability of neurophysiological tests (such as evoked potentials monitoring and electromyography) varied directly with hospital size (Table 18) . Magnetic resonance imaging was available to 40% of patients in hospitals with less than 500 beds and to 65% in hospitals with at least 500 beds. A megavoltage radiotherapy facility was available to the majority of patients, especially in the larger hospitals (Table 19) . The presence of a clinical research unit and investigative clinical protocols for treatment of brain-tumor patients was directly related to hospital size, although the percentage occurrence at all hospitals was not high. Physician training programs in neurosurgery, medical oncology, and radiation oncology were established in more hospitals of larger size; only about one-half of hospitals with less than 500 beds had such programs (Table 20) .
Discussion
Brain tumors occur with much less frequency than breast and primary lung cancer but more frequently than Hodgkin's disease. The most common brain tumor is a metastatic lesion from primary sites elsewhere, such as lung, breast, genitourinary tract, gastrointestinal, or skin. This survey gathered data only on primary brain tumors, which includes lesions of glial origins (astrocytic, oligodendroglial, and ependymal), presumed mesodermal origins (meningiomas, neurilemoma, and hemangioblastoma), other neuroectodermal types (ganglioneuroma, medulloblastoma, neuroblastoma, and pineal gland origins), and reticuloendothelium (lymphoma). Each of these tumor types has a benign and malignant form. It is rare for a malignant primary brain tumor to metastasize outside the CNS, although this occasionally happens (most often with medulloblastoma, neuroblastoma, and ependymoma). Therefore, the clinical challenge is usually that of disease control within the CNS rather than control of systemic spread. Certain of these tumors have a peak incidence during childhood; these include medulloblastoma, neuroblastoma, pineal region tumors, and ependymomas. ratings also correlated with an occipital lobe location of GBM and with a younger age overall. Although Karnofsky ratings tended to be lower at the conclusion of therapy for GBM and medulloblastoma and were considerably lower at the time of documented progression of disease following initial therapy, higher initial Karnofsky ratings were strong predictors of the 5-year survival rate. For the important large group of GBM patients, it is clear that patients selected for the most intensive treatment (surgery plus radiotherapy plus chemotherapy) had higher initial Karnofsky ratings than those who received surgery plus radiotherapy or, pal-ticularly, surgery alone. Surgery was performed in most (97%) cases, with the extent of resection in patients with GBM being dependent on age and Karnofsky rating. Generally, the 5-year survival rate was best when total surgical resections were attempted. The use of biopsy increased 3% from 1980 to 1985, probably reflecting the interest in CTassisted stereotactic technology. Surgical complications were not great; wound infections were less than 2%. Between 1980 and 1985, fewer children with brain tumors were initially treated with surgery plus radiotherapy (53% vs. 39%) and more were treated with surgery plus chemotherapy (0% vs. 5%), probably reflecting the evolving concern about injury to normal brain caused by radiotherapy in children less than 3 years of age.
Radiotherapy was frequently employed, since the majority of cases were anaplastic gliomas. There was a shift from use of cobalt sources to that of linear accelerators between 1980 and 1985, and the use of interstitial implants increased threefold during the interval. Chemotherapy was given to approximately l 1.9% of patients with anaplastic gliomas or medulloblastomas.
There were no more patients, adults or children, involved in investigative clinical protocols of therapy in 1985 than was the case in 1980. Although the percentage of potentially eligible patients for such studies who were entered into such treatments was small (7.6%), those in investigative studies had a threefold better 5-year survival rate. It is recognized that this enhanced survival statistic could be influenced by placing patients with higher Karnofsky ratings in such studies.
